nach oben

Erschienen in:

01.08.2012

ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer Treatment

verfasst von: Luis Cabezón-Gutiérrez, Parham Khosravi-Shahi, Victor Manuel Diaz-Muñoz-de-la-Espada, Jose Rafael Carrión-Galindo, Itziar Eraña-Tomás, María Castro-Otero

Erschienen in: Lung | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The anaplastic lymphoma kinase (ALK) tyrosine kinase (TK) receptor has emerged recently as a potentially relevant biomarker and therapeutic target in solid and hematologic tumors. A variety of alterations in the ALK gene, such as mutations, overexpression, amplification, translocations, or other structural rearrangements, have been implicated in human cancer tumorigenesis. In this article we review the potential role that ALK may have in lung tumor origin, the methodology to detect the different molecular alterations, and the most important clinical aspects of ALK alterations in NSCLC patients.

American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society, 2011. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011. Accessed 27 July 2011

Webb TR, Slavish J, George RE, Look AT et al (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9:331–356PubMedCrossRef

Lin E, Li L, Guan Y, Soriano R et al (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7:1466–1476PubMedCrossRef

Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M (2008) EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 98:1536–1539PubMedCrossRef

Janoueix-Lerosey I, Lequin D, Brugieres L et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967–970PubMedCrossRef

Soda M, Choi YL, Enomoto M, Takada S et al (2007) Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448:561–566PubMedCrossRef

Morris SW, Kirstein MN, Valentine MB et al (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 267(5196):316–317PubMed

Li R, Morris SW (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28(3):372–412PubMedCrossRef

Kelleher FC, McDermott R (2010) The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 46(13):2357–2368PubMedCrossRef

10.

Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C et al (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 276:16772–16779PubMedCrossRef

11.

Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT et al (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277:35990–35998PubMedCrossRef

12.

Tartari CJ, Gunby RH, Coluccia AM et al (2008) Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 283:3743–3750PubMedCrossRef

13.

Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425–437PubMedCrossRef

14.

Wellstein A, Toretsky JA (2011) Hunting ALK to feed targeted cancer therapy. Nat Med 17(3):290–291PubMedCrossRef

15.

Mossé YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215):930–935PubMedCrossRef

16.

Chen Z, Sasaki T, Tan X et al (2010) Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70(23):9827–9836PubMedCrossRef

17.

Palmer RH, Vernersson E, Grabbe C, Hallberg B (2009) Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420:345–361PubMedCrossRef

18.

Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275–4283PubMedCrossRef

19.

Shinmura K, Kageyama S, Tao H et al (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61:163–169PubMedCrossRef

20.

Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143–3149PubMedCrossRef

21.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203PubMedCrossRef

22.

Ladanyi M, Cavalchire G (1996) Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site. Genes Chromosomes Cancer 15:173–177PubMedCrossRef

23.

De Castro-Carpeño J, Perona R, Belda-Iniesta C (2011) Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. Clin Transl Oncol 13:774–779PubMedCrossRef

24.

Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA (2006) Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 103:9964–9969PubMedCrossRef

25.

Chiarle R, Simmons WJ, Cai H et al (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623–629PubMedCrossRef

26.

Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96:4319–4327PubMed

27.

Zou HY, Li Q, Lee JH et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408–4417PubMedCrossRef

28.

Armstrong F, Duplantier MM, Trempat P et al (2004) Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23:6071–6082PubMedCrossRef

29.

McDermott U, Iafrate AJ, Gray NS et al (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389–3395PubMedCrossRef

30.

Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314–3322PubMedCrossRef

31.

Perner S, Wagner PL, Demichelis F et al (2008) EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10:298–302PubMed

32.

Salido M, Pijuan L, Martínez-Aviles L et al (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 6:21–27PubMedCrossRef

33.

Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703PubMedCrossRef

34.

Camidge DR, Bang YJ, Kwak EL et al. (2011) Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 29(ASCO Meeting Abstr Suppl): Abstr 2501

35.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef

36.

Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597PubMedCrossRef

37.

Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004–1012PubMedCrossRef

38.

Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734–1739PubMedCrossRef

39.

Bossi RT, Saccardo MB, Ardini E et al (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49:6813–6825PubMedCrossRef

40.

Heuckmann JM, Hölzel M, Sos ML et al (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17(23):7394–7401PubMedCrossRef

41.

Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPMALK. Proc Natl Acad Sci USA 104:270–275PubMedCrossRef

42.

Van Roosbroeck K, Cools J, Dierickx D et al (2010) ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95:509–513PubMedCrossRef

43.

Sabbatini P, Korenchuk S, Rowand JL et al (2009) GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 8:2811–2820PubMedCrossRef

44.

Rabindran SK, Sabbatini P, Korenchuk et al. (2010) Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo. Proceedings of the 100th annual meeting of the American association for cancer research (AACR), Denver, CO, 27–30 September 2010

45.

Pulford K, Morris SW, Turturro F (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199:330–358PubMedCrossRef

46.

Ardini E, Menichincheri M, De Ponti C et al. (2009) Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Therapeutics 8(12 Suppl 1): abstr 243

47.

Shakespeare WC, Fantin VR, Wang F et al. (2009) Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK). Proceedings of the 100th annual meeting of the American association for cancer research (AACR), Denver, CO, 27–30 September 2010, abstract 3738

48.

Rivera VM, Anjum R, Wang F et al. (2010) Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of anaplastic lymphoma kinase (ALK). Proceedings of the 101th annual meeting of the American association for cancer research (AACR), Washington, DC, 17–21 April 2010, poster 3623

49.

Zhang S, Wang F, Keats J, Ning Y, Wardwell SD (2010) AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Proceedings of the 101th annual meeting of the American association for cancer research (AACR), Washington, DC, 17–21 April 2010, poster LB-298

50.

Rodig SJ, Mino-Kenudson M, Dacic S et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216–5223PubMedCrossRef

51.

Choi YL, Takeuchi K, Soda M et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971–4976PubMedCrossRef

Titel: ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer Treatment
verfasst von: Luis Cabezón-Gutiérrez
Parham Khosravi-Shahi
Victor Manuel Diaz-Muñoz-de-la-Espada
Jose Rafael Carrión-Galindo
Itziar Eraña-Tomás
María Castro-Otero
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: Lung / Ausgabe 4/2012
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-012-9391-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Effects of Extra-Fine Inhaled and Oral Corticosteroids on Alveolar Nitric Oxide in COPD

Reversed Halo Sign on Computed Tomography: State-of-the-Art Review

Emerging Therapies for Obstructive Sleep Apnea

The Validity of Static Lung Compliance in Asbestos-induced Diseases

Idiopathic Pulmonary Fibrosis is Associated with Circulating Antiepithelial Antibodies